Wolf Popper LLP Announces Investigation On Behalf Of Billiontoone, Inc. Investors
BillionToOne provides genetic testing and recently held its initial public offering on November 5 2025 at $60.00 per share.
Before the market opened on November 18, 2026, short seller Fuzzy Panda Research published a report entitled BillionToOne (BLLN) – Undisclosed Fraudulent Billing Allegations; Deductible Capping Scheme Formers Say is“Against the Law;” Dr's Debunk Oncology Hype. The report alleges multiple issues including BillionToOne hasn't disclosed Tennessee is investigating the company for Medicaid fraud, BillionToOne bills insurers for tests the pregnant women don't need, BillionToOne reduces or eliminates deductibles and copays to encourage doctors and patients to use its test, and BillionToOne overpays doctors for blood draws and supplies free phlebotomists who also perform unrelated work. On that news, BillionToOne's stock price fell $5.96 per share to $91.54, down 6.1% on heavy volume.
Investors who suffered losses trading in BillionToOne common stock and who would like to discuss the investigation should contact Adam Savett at (212) 451-9655, or ....
Wolf Popper has successfully recovered billions of dollars for defrauded investors. Wolf Popper's reputation and expertise have been repeatedly recognized by courts that have appointed the firm to major positions in securities litigation. For more information about Wolf Popper, please visit the Firm's website at .
May Be Considered Attorney Advertising in Certain Jurisdictions.
Prior Results Do Not Guarantee a Similar Outcome.
Wolf Popper LLP
Adam Savett. Esq.
570 Lexington Avenue
New York, NY 10022
Tel.: (212) 451-9655
Email: ...

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.

Comments
No comment